Ossium Health ships cryopreserved deceased-donor bone marrow for 29 transplants
The startup banked bone marrow recovered from deceased organ donor vertebrae and reported 100% engraftment in evaluable clinical cases.
American biotech company Ossium Health has supplied cryopreserved bone marrow for 29 clinical transplants, reporting that compatible units can be delivered within 72 hours of a medical request, according to ecosistemastartup 
ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. The company, founded in 2016 in San Francisco, extracts hematopoietic stem cells from the vertebrae of deceased organ donors rather than living donors' pelvises, processing them at its Indianapolis biobank facility ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. The process takes four to six hours per donor, producing enough material to treat an average of three patients, with storage maintained in cryogenic tanks near minus 150 degrees Celsius ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗.
Clinical results and biological findings
At the 2026 AABB Annual Meeting, Ossium reported an 86% median post-thaw viability of CD34+ stem cells and a 100% engraftment rate across 24 evaluable patients ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. In its HOPE I program for acute myeloid leukemia, four out of five evaluable patients received grafts matching only 4 of 8 HLA alleles, with all achieving engraftment and zero relapses or graft failures observed ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. Global survival stood at 100% at day 180, though one patient died on day 282 from an influenza-associated infection ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗.
Laboratory studies conducted with the University of Kansas Medical Center showed that a low-dose pulse of interleukin-6 (IL-6) occurring after brain death doubled the proportion of primitive hematopoietic stem cells and enhanced stress resistance ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗.
Biobanking infrastructure and trials
Ossium currently collaborates with organ procurement organizations representing 60% of the United States procurement system ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. The company operates an FDA-registered facility with a CLIA-certified laboratory, partially backed by BARDA contract funding ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. A 300-patient multicenter clinical trial, designated PRESERVE II, is underway to directly evaluate cryopreserved deceased-donor bone marrow against two conventional living-donor alternatives ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗.
In 2026, the company performed its first pediatric transplant on a 14-year-old recipient ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗. Ossium plans a full commercial rollout of its banked deceased-donor bone marrow inventory in the United States in February 2027 ecosistemastartup.comecosistemastartupecosistemastartup.comOpen source ↗.
